Pyridoxal 5'-phosphate-dependent histidine decarboxylase. Inactivation by alpha-fluoromethylhistidine and comparative sequences at the inhibitor- and coenzyme-binding sites.
Pyridoxal phosphate-dependent histidine decarboxylase from Morganella morganii AM-15 was inactivated by (S)-alpha-fluoromethylhistidine by a pseudo first-order reaction, with KI and k inact values of 0.1 mM and 32.2 min-1, respectively, and was most efficient at pH 6.5-7.0. Both L-histidine and the competitive inhibitor, L-histidine methyl ester, protected against inactivation. The apoenzyme was not inactivated. These findings indicate that inhibition is a mechanism-based process. Under optimal conditions a single molecule of alpha-fluoromethylhistidine inactivates one enzyme subunit, indicating that no escaping side reaction occurs during the inactivation process. The bound inactivator is not released by dialysis of the native protein but is released upon denaturation by heat or urea. This released product was not fully characterized, but it contains the tritium of ring-labeled alpha-fluoromethyl-[3H]histidine, exhibits the spectral properties of a 3-hydroxypyridine derivative, and does not yield any amino acids on hydrolysis. The label was much more stable following borohydride reduction of the inactivated protein, and a tryptic peptide containing the modified residue was isolated. Sequencing of this peptide and the corresponding peptide from the native enzyme revealed that the inactivator binds to a serine residue of the holoenzyme. Two P-pyridoxyl peptides from tryptic or CNBr digests of the NaBH4-reduced enzyme were also isolated. Sequence and compositional data obtained with these peptides showed that the serine residue to which the inhibitor binds is not near the lysine residue that binds pyridoxal-P in the primary sequence of the protein, although the two residues must be near one another in the three-dimensional structure to account for these results. A speculative mechanism for inactivation, consistent with the experimental findings, is presented.
D000595:Amino Acid Sequence; D001665:Binding Sites; D001894:Borohydrides / Q000494:pharmacology; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003488:Cyanogen Bromide / Q000494:pharmacology; D006639:Histidine / Q000031:analogs & derivatives* / Q000378:metabolism; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors*; D007700:Kinetics; D008762:Methylhistidines / Q000494:pharmacology*; D011489:Protein Denaturation; D011511:Proteus / Q000201:enzymology*; D011732:Pyridoxal Phosphate / Q000378:metabolism*; D013053:Spectrophotometry; D013997:Time Factors; D014357:Trypsin / Q000378:metabolism
D001894:Borohydrides; D008762:Methylhistidines; D006639:Histidine; D011732:Pyridoxal Phosphate; C028309:alpha-fluoromethylhistidine; C025364:sodium borohydride; D014357:Trypsin; D002262:Carboxy-Lyases; D006640:Histidine Decarboxylase; D003488:Cyanogen Bromide